SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
In this photo illustration, the Moderna logo is seen displayed on a smartphone screen with the logo of the Covax Facility in the background. (Photo Illustration: Rafael Henrique/SOPA Images/LightRocket via Getty Images)
Oxfam Files SEC Complaint Against Moderna for Deceiving Investors Over Patent Dispute
"Instead of being transparent and using its life-saving technology to help curb the pandemic," said the anti-poverty group, "Moderna is doing the opposite."
Dec 21, 2021
Oxfam America filed a complaint Tuesday with the Securities and Exchange Commission that accuses vaccine maker Moderna of making "deceptive and ambiguous statements" that "were designed to hide damaging information from investors," in violation of disclosure laws.
Those alleged "misleading statements" center on Moderna's ongoing dispute with the U.S. government regarding intellectual property rights to the mRNA Covid-19 vaccine developed in collaboration with the National Institutes of Health, and the language the company used to convey that fight in reports to shareholders.
"The fact that Moderna relies so heavily upon this disputed product as the exclusive source of its profits, that its vaccine is subject to intense public and governmental scrutiny, and that an average reasonable investor would have found the U.S. government-Moderna dispute a critical element in determining the stock's value all indicate the company failed to disclose a material risk," the whistleblower complaint, seen by Common Dreams, states.
The filing comes amid sustained criticism of Big Pharma's control over life-saving Covid-19 vaccines--including Moderna's--and demands that pharmaceutical companies share their vaccine technology with the world to help counter stark and ongoing global vaccine inequity. That call has only become more urgent in light of the highly transmissible Omicron variant.
The complaint comes just days after Moderna put at least a temporary pause on its fight with the National Institutes of Health (NIH) over patent rights, because the company put a hold on acquiring the patent. As the Washington Post reported:
Moderna had disputed some claims by NIH that federal scientists were responsible for the invention of the company's mRNA coronavirus vaccine, complicating the government's ability to license the patent and share it with vaccine makers around the world. Government scientists worked with Moderna in January 2020 to rapidly develop the spike protein technology that underpins the vaccine.
While Moderna had acknowledged NIH-funded scientists' role in devising the vaccine, some of its patent applications excluded the government's contributions, advocacy group Public Citizen told reporters last month.
"Moderna believes that its scientists invented the specific mRNA sequence at the heart of the patent in question," according to the company's statement. "The company acknowledges that NIH feels equally strongly that its scientists should be listed as co-inventors for their contemporaneous work on the protein sequence."
"Patent holders could seek a cut of the shot's billions of dollars in sales," the Wall Street Journal noted, "though NIH hasn't said whether it is interested in royalties."
Last week's development, according to the filing, doesn't eliminate the threat of litigation with the federal government but simply "kicks the can down the road."
It's also evidence Moderna "is likely aware that this patent dispute is taking a reputational toll and could lead to a costly lawsuit," the filing states.
Moderna did not, however, clearly convey this information in its recent reports to shareholders.
Instead, the company says it "may be subject to legal proceedings" and as such concealed the fact that "the NIH is openly contemplating litigation because of the company's refusal to share inventorship credit" and hid "damaging information from investors."
Diana Kearney, senior legal advisor for legal and shareholder advocacy at Oxfam America, said Moderna must be held accountable.
"Instead of being transparent and using its life-saving technology to help curb the pandemic," Kearney said in a statement, "Moderna is doing the opposite, obfuscating its patent dispute with the U.S. government, ignoring the death and suffering of millions worldwide, and declining to share their technology to help alleviate the stranglehold that Covid-19 has placed on the global economy."
"Few times in history has a single corporation exercised such a massive influence on the world's trajectory, impacting nearly all of humankind's physical, mental, and financial health," she added, calling Moderna "uniquely positioned to speed the end of the pandemic if it is transparent and shares its technology."
"In light of the company's misguided pursuit of short-term profit over transparency for its investors, and the deadly consequences this may have for millions," said Kearney, "Oxfam is calling on the SEC to investigate and help hold the company to account."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Oxfam America filed a complaint Tuesday with the Securities and Exchange Commission that accuses vaccine maker Moderna of making "deceptive and ambiguous statements" that "were designed to hide damaging information from investors," in violation of disclosure laws.
Those alleged "misleading statements" center on Moderna's ongoing dispute with the U.S. government regarding intellectual property rights to the mRNA Covid-19 vaccine developed in collaboration with the National Institutes of Health, and the language the company used to convey that fight in reports to shareholders.
"The fact that Moderna relies so heavily upon this disputed product as the exclusive source of its profits, that its vaccine is subject to intense public and governmental scrutiny, and that an average reasonable investor would have found the U.S. government-Moderna dispute a critical element in determining the stock's value all indicate the company failed to disclose a material risk," the whistleblower complaint, seen by Common Dreams, states.
The filing comes amid sustained criticism of Big Pharma's control over life-saving Covid-19 vaccines--including Moderna's--and demands that pharmaceutical companies share their vaccine technology with the world to help counter stark and ongoing global vaccine inequity. That call has only become more urgent in light of the highly transmissible Omicron variant.
The complaint comes just days after Moderna put at least a temporary pause on its fight with the National Institutes of Health (NIH) over patent rights, because the company put a hold on acquiring the patent. As the Washington Post reported:
Moderna had disputed some claims by NIH that federal scientists were responsible for the invention of the company's mRNA coronavirus vaccine, complicating the government's ability to license the patent and share it with vaccine makers around the world. Government scientists worked with Moderna in January 2020 to rapidly develop the spike protein technology that underpins the vaccine.
While Moderna had acknowledged NIH-funded scientists' role in devising the vaccine, some of its patent applications excluded the government's contributions, advocacy group Public Citizen told reporters last month.
"Moderna believes that its scientists invented the specific mRNA sequence at the heart of the patent in question," according to the company's statement. "The company acknowledges that NIH feels equally strongly that its scientists should be listed as co-inventors for their contemporaneous work on the protein sequence."
"Patent holders could seek a cut of the shot's billions of dollars in sales," the Wall Street Journal noted, "though NIH hasn't said whether it is interested in royalties."
Last week's development, according to the filing, doesn't eliminate the threat of litigation with the federal government but simply "kicks the can down the road."
It's also evidence Moderna "is likely aware that this patent dispute is taking a reputational toll and could lead to a costly lawsuit," the filing states.
Moderna did not, however, clearly convey this information in its recent reports to shareholders.
Instead, the company says it "may be subject to legal proceedings" and as such concealed the fact that "the NIH is openly contemplating litigation because of the company's refusal to share inventorship credit" and hid "damaging information from investors."
Diana Kearney, senior legal advisor for legal and shareholder advocacy at Oxfam America, said Moderna must be held accountable.
"Instead of being transparent and using its life-saving technology to help curb the pandemic," Kearney said in a statement, "Moderna is doing the opposite, obfuscating its patent dispute with the U.S. government, ignoring the death and suffering of millions worldwide, and declining to share their technology to help alleviate the stranglehold that Covid-19 has placed on the global economy."
"Few times in history has a single corporation exercised such a massive influence on the world's trajectory, impacting nearly all of humankind's physical, mental, and financial health," she added, calling Moderna "uniquely positioned to speed the end of the pandemic if it is transparent and shares its technology."
"In light of the company's misguided pursuit of short-term profit over transparency for its investors, and the deadly consequences this may have for millions," said Kearney, "Oxfam is calling on the SEC to investigate and help hold the company to account."
Oxfam America filed a complaint Tuesday with the Securities and Exchange Commission that accuses vaccine maker Moderna of making "deceptive and ambiguous statements" that "were designed to hide damaging information from investors," in violation of disclosure laws.
Those alleged "misleading statements" center on Moderna's ongoing dispute with the U.S. government regarding intellectual property rights to the mRNA Covid-19 vaccine developed in collaboration with the National Institutes of Health, and the language the company used to convey that fight in reports to shareholders.
"The fact that Moderna relies so heavily upon this disputed product as the exclusive source of its profits, that its vaccine is subject to intense public and governmental scrutiny, and that an average reasonable investor would have found the U.S. government-Moderna dispute a critical element in determining the stock's value all indicate the company failed to disclose a material risk," the whistleblower complaint, seen by Common Dreams, states.
The filing comes amid sustained criticism of Big Pharma's control over life-saving Covid-19 vaccines--including Moderna's--and demands that pharmaceutical companies share their vaccine technology with the world to help counter stark and ongoing global vaccine inequity. That call has only become more urgent in light of the highly transmissible Omicron variant.
The complaint comes just days after Moderna put at least a temporary pause on its fight with the National Institutes of Health (NIH) over patent rights, because the company put a hold on acquiring the patent. As the Washington Post reported:
Moderna had disputed some claims by NIH that federal scientists were responsible for the invention of the company's mRNA coronavirus vaccine, complicating the government's ability to license the patent and share it with vaccine makers around the world. Government scientists worked with Moderna in January 2020 to rapidly develop the spike protein technology that underpins the vaccine.
While Moderna had acknowledged NIH-funded scientists' role in devising the vaccine, some of its patent applications excluded the government's contributions, advocacy group Public Citizen told reporters last month.
"Moderna believes that its scientists invented the specific mRNA sequence at the heart of the patent in question," according to the company's statement. "The company acknowledges that NIH feels equally strongly that its scientists should be listed as co-inventors for their contemporaneous work on the protein sequence."
"Patent holders could seek a cut of the shot's billions of dollars in sales," the Wall Street Journal noted, "though NIH hasn't said whether it is interested in royalties."
Last week's development, according to the filing, doesn't eliminate the threat of litigation with the federal government but simply "kicks the can down the road."
It's also evidence Moderna "is likely aware that this patent dispute is taking a reputational toll and could lead to a costly lawsuit," the filing states.
Moderna did not, however, clearly convey this information in its recent reports to shareholders.
Instead, the company says it "may be subject to legal proceedings" and as such concealed the fact that "the NIH is openly contemplating litigation because of the company's refusal to share inventorship credit" and hid "damaging information from investors."
Diana Kearney, senior legal advisor for legal and shareholder advocacy at Oxfam America, said Moderna must be held accountable.
"Instead of being transparent and using its life-saving technology to help curb the pandemic," Kearney said in a statement, "Moderna is doing the opposite, obfuscating its patent dispute with the U.S. government, ignoring the death and suffering of millions worldwide, and declining to share their technology to help alleviate the stranglehold that Covid-19 has placed on the global economy."
"Few times in history has a single corporation exercised such a massive influence on the world's trajectory, impacting nearly all of humankind's physical, mental, and financial health," she added, calling Moderna "uniquely positioned to speed the end of the pandemic if it is transparent and shares its technology."
"In light of the company's misguided pursuit of short-term profit over transparency for its investors, and the deadly consequences this may have for millions," said Kearney, "Oxfam is calling on the SEC to investigate and help hold the company to account."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.